Introduction
Although gene therapy was initially envisioned as a means for the delivery of single genes in the treatment of monogenic diseases, the same methods can be utilized for the delivery of multiple genes to treat pathologic conditions resulting from multifactorial or multigenic processes such as cancer. This strategy will require the development of gene transfer vehicles which can accommodate extensive foreign genetic sequences. The human herpesviruses are large DNA viruses which have the natural ability to persist in a life-long nonintegrated state within the nucleus, without causing disease in an immune competent host. Among the herpesviruses, HSV-1 is a particularly attractive candidate for vector development because the virus has a broad host range, does not require cell division for infection and gene expression, and its 152 kb genome is highly recombinogenic but contains few spliced genes, features that facilitate genetic manipulation. Of the 84 known HSV-1 genes, approximately half are dispensable (nonessential) for virus repli- 1 On infection, HSV genes are expressed in a sequential interdependent order. 2 Transcription of the five HSV immediate-early (IE) genes, ICP0, ICP4, ICP22, ICP27 and ICP47, begins on viral entry into the nucleus. Expression of these genes is controlled by promoters containing an enhancer element responsive to the viral transactivator VP16, a structural protein which is transported into the nucleus along with the viral DNA. [3] [4] [5] Expression of the IE gene products initiates a cascade of viral gene expression, resulting in the synthesis first of early (E) genes which primarily encode enzyme functions required for DNA replication, followed by late (L) genes coding principally for structural components of the virion. Only two of the IE genes, ICP4 and ICP27, are essential in that their products are required for the expression of E and L genes.
6-11 L gene expression requires both these IE gene functions and viral DNA synthesis in order to proceed. The IE gene products ICP0 and ICP22 contribute to viral gene transcription but are not essential to virus replication. [12] [13] [14] ICP0 is a promiscuous transactivator acting before the start of transcription, but it is not a DNA binding protein. 15, 16 ICP22 has been found to regulate the level of ICP0 expression. 17, 18 The remaining IE gene, ICP47, does not affect transcription but rather has been reported to interfere with a transporter function (TAP) that is responsible for loading MHC class I molecules with antigenic peptides. [19] [20] [21] [22] The rigid temporal cascade of viral gene expression makes the construction of replication incompetent mutants straightforward. Removal of one essential IE gene prevents expression of the later genes in the gene expression cascade, resulting in a mutant incapable of producing progeny viral particles. However, a mutant deleted for a single IE gene (ICP4) is cytotoxic for cells in culture. 6, 23 This toxicity is a function of the remaining IE genes which continue to be expressed in an ICP4 − virus and, with the exception of ICP47, produce products that are toxic for cells. 23 The simultaneous removal of multiple IE genes has been shown to reduce the toxicity of replication incompetent mutants and we reasoned that this should permit prolonged transgene expression. [24] [25] [26] [27] However, this benefit must be weighed separately for each IE gene against the potential repercussions of deleting that gene. For example, deletion of the ICP0 gene would eliminate the potent and promiscuous transcriptional activator produced by this gene and reduce transgene expression accordingly. 26 On the other hand, ICP22 has been reported to regulate the level of ICP0 expression such that deletion of ICP22 would not only reduce vector toxicity but should also enhance the persistence of ICP0 activity and consequently transgene expression. 18, 28 Likewise, deletion of ICP47 may offer advantages unrelated to cytotoxicity. For example, by restoring normal MHC class I expression, elimination of ICP47 can potentially enhance the effectiveness of transgenes designed to increase tumor immunity. [19] [20] [21] [22] There are a number of nonessential viral genes in the E and L gene classes which may be deleted to provide additional packaging space for transgene cassettes. Because these genes are nonessential, their removal does not strictly require the development of complementing cell lines for viral propagation. Included among these accessory genes are many of the nonessential glycoprotein genes and genes whose products contribute to viral DNA synthesis in nondividing cells, such as U L 23 encoding thymidine kinase 29 and U L 39/40 encoding ribonucleotide reductase. 30, 31 Also included are genes which enhance the ability of the virus to prevent cellmediated interference with viral gene expression and protein synthesis (eg U L 41 encoding the virus host shutoff (vhs) function) [32] [33] [34] and genes that contribute to specialized aspects of the virus life cycle such as the establishment and maintenance of latency or reactivation from latency.
In order to test the idea that a relatively nontoxic multigene-containing vector could be developed for specific applications requiring short-term high-level expression of multiple products, we constructed an HSV-1 mutant deleted for nine viral functions including the IE genes ICP4, ICP22, ICP27 and ICP47, retaining only ICP0 because of its suggested role in improving transgene expression. 27 This mutant vector was further engineered to express five transgenes chosen for their potential to synergize in tumor cell killing and induction of antitumor immunity. We selected three genes for soluble human cytokines (IL-2, GM-CSF and interferon ␥ (IFN␥) ), the human B7.1 gene encoding a surface antigen (CD80) and the HSV thymidine kinase (tk) gene. CD80 is an immune costimulatory surface molecule required for efficient T cell activation. 35 The HSVTK protein converts the nontoxic pro-drug ganciclovir (GCV) into a defective nucleoside whose incorporation into cellular DNA blocks DNA synthesis, resulting in the death of dividing cells. 36, 37 Each of these transgenes was placed under the control of either an HSV or human cytomegalovirus (HCMV) IE promoter (IEp) in order to achieve expression from the replication incompetent vector.
The novel vector showed substantially reduced cytotoxicity compared with vectors deleted for fewer IE genes, allowing for efficient transduction of cells in culture and vigorous transgene expression. Expression of individual transgenes from the mutant vector persisted for up to 1 week after infection (PI) and was not compromised by the presence of multiple transgene expression cassettes. In addition, we showed that vectors with new sets of transgenes could be derived efficiently. Thus, this vector design should prove useful for a variety of applications where high-level transient expression of multiple transgenes is required. Figure 1a shows the structures of the different HSV-1 vectors used in this report; Figure 1b lists the genotypes and transgenes of each. The new vectors described here were derived directly or sequentially from the ICP4 null mutant d120, 6 a derivative of wild-type KOS virus, by a previously described transgene insertion procedure utilizing PacI restriction sites engineered into the recipient viral genome. 38 Pertinent features of the transgene donor plasmids are listed in Table 1 and vector construction details will be presented elsewhere.
Results

Vectors
Transgene insertions and other critical vector modifications were confirmed by Southern blot analysis. As an example, Figure 2 shows analyses of different portions of the HX86Z genome confirming the presence and proper location of each of the five transgene expression cassettes recombined into this multigene vector. HX86Z was routinely grown to titers of 5 × 10 8 plaque forming units (p.f.u.) per 10 8 complementing cells with particle (determined by EM) to p.f.u. ratios ranging from 100:1 to 50:1.
Relative vector cytotoxicity
Initial experiments were performed to determine whether the deletion of multiple IE genes from the HSV-1 genome would result in reduced cytotoxicity compared with d120, which lacks just a single IE gene (ICP4). 6 The survival of Gombos human primary melanoma cells was compared following infection at a multiplicity (MOI) of 5 with the following mutant vectors deleted for one, two or four IE genes (see Figure 1 ): (1) HG.1, which lacks a functional ICP4 gene but carries an hGM-CSF transgene expression cassette in the U L 41 locus; (2) 167.1, which lacks functional genes for ICP4 as well as ICP47, the latter due to interruption by an hIL-2 expression cassette; and (3) HX86, a quadruple IE gene knock-out mutant combining the modifications of 167.1 (ICP4 − ICP47 − ) with a loss of a functional ICP22 gene due to insertion of a transgene (hB7.1) and deletion of the ICP27 gene; HX86 had, in addition, the same hGM-CSF insertion as HG.1. The results in Figure 3a show that HG.1, the single IE gene deletion mutant, caused rapid cell death resulting in decreases of 60% at 24 h and 80% at 48 h PI in the number of viable cells, which can be compared with increases of 25 and 40% for uninfected cells at the same time-points. The double IE gene knock-out (167.1) showed a similar profile, although the cell count at 24 h was somewhat higher than for HG.1; it is not clear whether this is significant and may point to a delayed onset of cell growth inhibition and/or killing. In contrast, the curve for the quadruple knock-out mutant HX86 suggested a clear and significant delay in the onset of cell growth inhibition and/or killing, although the rate of cell loss between 24 h and 96 h PI was not dramatically different from the rates displayed by the single and double mutants. These results indicated that HX86 represents an improved vector background for HSV-1-mediated gene transfer compared with vectors lacking only a functional ICP4 gene, at least for short-term applications. In addition, we observed essentially no reduction in the number of viable cells following infection with HX86 at an MOI of 1 (compared with an MOI of 5 used in the previous experiment), whereas infection with the single knock-out mutant HG.1 at this lower MOI reduced the number of viable cells by 50% (data not shown). Together, these results imply that HSV-1 vectors lacking multiple IE functions are more suitable than previous first generation HSV-1 vectors for short-term and perhaps for long-term gene transfer applications.
Expression of soluble cytokines
To determine if the deletion of multiple IE genes from the HSV-1 genome would affect the level and duration of transgene expression, Gombos cells infected with the multigene vector HX86 were tested for simultaneous expression of the four transgenes contained in this vector. Expression of the hGM-CSF transgene in U L 41 from an ICP0 promoter and the hIL-2 transgene in the ICP47 locus from the HCMV-IE promoter was demonstrated by quantitative ELISA for the secreted products of these 
genes in the culture medium (Figure 3b and c). Expression peaked in the first 24-48 h following infection, but continued for 6 days at levels consistently greater than uninfected and virus-infected controls ( Figure 3b , 50 pg and c, 10 ng). Compared with single (HG.1; Figure  3b ) or double (167.1; Figure 3c ) IE knock-out vectors with the hGM-CSF (HG.1) or IL-2 (167.1) expression cassettes in the same configuration, expression from HX86 was both greater in amount and longer in duration. These results may be attributable to deletion of multiple IE genes which contribute to vector toxicity.
Expression and functional assay of HSVTK Because E viral gene expression is reduced by two orders of magnitude in viral mutants deleted for ICP4, 7, 39 an IE promoter was used to express the E gene HSVtk, whose activity in conjunction with the pro-drug GCV can be exploited for the purpose of local tumor cell killing. The immunoblot in Figure 4a shows that tk protein was readily detectable in Vero cells 24 h after infection with HX86, which had the ICP4 promoter controlling the tk gene, but not after infection with another quadruple IE gene knockout mutant, THZ.2 (see Figure 1) , in which the tk gene was controlled by its native promoter.
HSVtk expression from HX86 was also tested independently by measuring GCV-dependent cell killing. Vero cells were infected at an MOI of 5 (compared with 10 in the previous experiment), the cells were passaged into medium with or without GCV, and viable cells were counted 48, 72 and 96 h PI. Infected cultures did not survive on exposure to GCV but GCV had little effect on uninfected cells (Figure 4b ). These results confirmed that HX86 expressed the tk gene and demonstrated that the product was functional. A similar experiment with Gombos cells also showed GCV-dependent killing at 72 h PI, but the effect was much less dramatic; this was not surprising given the survival curve ( Figure 3a ) for HX86-infected cells because TK-activated GCV only kills dividing cells. Together, these experiments showed that the E gene HSVtk can be expressed from the ICP4 promoter in the absence of ICP4 protein and that the product is biologically active.
Figure 2 Southern blots of multigene viral mutant HX86Z. (a) Pairwise comparisons of relevant portions of the genome maps of d120 and HX86Z, and locations of hybridization probes. Each comparison is named at the left for the transgene-recipient locus or loci pictured. The genome backbone is depicted as a horizontal line, repeat regions as open boxes, HSV-1 recipient genes as black bars, and inserted expression cassettes as gray boxes with
Expression of hB7.1
Like the hIL-2 gene in the ICP47 locus, the hB7.1 gene in the ICP22 locus of HX86 was controlled by the HCMV IE promoter. Expression of this fourth transgene of HX86 was measured by flow cytometry (FACS) analysis 24 h after infection, taking advantage of the cell surface localization of CD80, the product of the hB7.1 gene. Figure  5 illustrates that HX86-infected Gombos cells expressed increased levels of surface CD80 compared with uninfected controls or cells infected with the control vector THZ.3, which had the same IE genes knocked out as Insertion and expression of a fifth transgene HSV-1 contains a large number of nonessential genes representing at least 50 kb of viral coding sequences 1 and HX86 could therefore potentially accept additional transgenes. We tested if we could add the gene for IFN␥ to complement the four antitumor activities already expressed from HX86. This was accomplished by a twostep procedure involving, first, introduction by conventional means of a reporter gene flanked by PacI restriction sites not otherwise found in the viral genome, and second, PacI digestion-facilitated replacement of the reporter cassette by an IFN␥ expression cassette. 38 Due to the efficiency of the second step (see below), this procedure permits the rapid generation of vectors with different transgenes at the locus targeted in the first step, which should facilitate the identification of optimal combinations of transgene functions for individual applications. We tested if the reporter and IFN␥ genes could be expressed from within U L 44, a nonessential gene whose product, glycoprotein C (gC), enhances infectivity. [40] [41] [42] For the first step, a plasmid with U L 44 sequences interrupted by an HCMV IEp-lacZ expression cassette was modified by engineering PacI restriction sites at the boundaries of the lacZ insertion. Cotransfection of linearized plasmid with HX86 DNA resulted in approximately 5% recombinant virus expressing lacZ from within the viral gC locus, as confirmed by Southern blot analysis of isolated recombinant HX86Z ( Figure 2) ; the mutant virus was resistant to neutralization by a pool of gC-specific complement-dependent neutralizing monoclonal antibodies using previously described methods 43, 44 (data not shown), demonstrating that gC was not expressed. The isolation of a properly structured recombinant virus based on a color reaction requiring the lacZ gene product ␤-galactosidase showed that a fifth transgene inserted into HX86 could be expressed from within the U L 44 locus in the Vero-derived ICP4-/ICP27-complementing 7B cells 24 used to generate the recombinant. In addition, we used a quantitative assay (ONPG) to measure lacZ expression in Gombos cells. As shown in Figure  6a , HX86Z infection at a multiplicity of 5 yielded nearly 0.2 units of ␤-galactosidase activity per 10 6 Gombos cells at 24 h PI compared with negligible activity in HX86-infected or uninfected Gombos cells; Figure 6b shows that the total amount of cell protein was the same for infected and uninfected cells, indicating that no cell lysis had occurred in the control or experimental infections. It can be concluded from these results that the lacZ transgene inserted into U L 44 of HX86 can be expressed in at least two different cell types.
In the second step, PacI digestion of HX86Z viral DNA was used to promote the replacement of the lacZ reporter gene by the IFN␥ gene. Illustrating the efficiency of this procedure, cotransfection of PacI-digested HX86Z DNA with a plasmid containing U L 44 interrupted by an HCMV-hIFN␥ expression cassette produced a new recombinant virus, HX86G containing the hIFN␥ transgene in place of the lacZ gene of HX86Z in greater than 80% of isolated viral plaques, as measured by a loss of chromogenic ␤-galactosidase activity. This corresponded with a recombination frequency comparable with that exhibited by replication defective single IE gene deletion mutants of HSV-1 using the same procedure, demonstrating that the generation of recombinant virus from the highly engineered HX86Z genome was not impaired by the multiple IE gene deletions or transgene insertions in the parent vector. IFN␥ production by Gombos cells infected with the new HX86G vector was measured by ELISA (Figure 6c) , showing significant secretion with a less dramatic drop-off than observed earlier for two different cytokines expressed from HX86 (see Figure 3) . Together, these experiments demonstrated that our multigene vector HX86 could be manipulated to express additional transgenes of choice and that the methods employed to generate the desirable vectors were effective.
Effect of serial insertions on expression of individual transgene products
Expression of the initial four transgenes of HX86 by HX86Z and HX86G was verified next, demonstrating that sequential insertion of transgene expression constructs by the PacI method into the U L 44 locus could be performed without compromising expression of the HX86 transgenes (data not shown). To determine whether the presence of multiple transgenes affected the expression of individual transgenes, the amounts of hGM-CSF produced from the ICP0 IE promoter recombined into U L 41 were compared between vectors containing three, four or five transgenes (Figure 7) . The three-transgene vector HGZ.25 (see Figure 1b) and the four-transgene vector HX86 expressed similar levels of hGM-CSF, but expression from the five-transgene vector HX86G was approximately two-fold lower; a similar reduction was observed for HX86Z compared with HX86. These reductions for HX86G and HX86Z can be ascribed to diminished transduction efficiencies because the fifth transgene in both vectors disrupted the gene for gC, an envelope glycoprotein that contributes to efficient virus attachment, [40] [41] [42] but this remains to be confirmed. Thus, the results indicated that transgene expression can be affected by the presence of additional expression cassettes, but the efficiency of transduction and expression may depend on the viral locus of transgene insertion.
Figure 7 Effect of serial transgene cassette insertion on GM-CSF expression from multiply deleted replication incompetent HSV-1 vectors. 5 × 10 5 Gombos cells were infected with the recombinant vectors HGZ.25, HX86 or HX86G at MOIs of 5, washed and plated. Media were replaced at 24 h intervals over a 5 day period following infection and the withdrawn media were assayed for GM-CSF protein by ELISA.
Insertion of IL-2 at the ICP47 locus restores normal MHC class I cell surface expression Infection of human cells by HSV-1 has been shown to result in a reduction of surface expression of class I MHC molecules. [19] [20] [21] [22] This phenomenon has been attributed to ICP47, an HSV-1 IE gene product capable of blocking TAP-mediated translocation of antigen-derived peptides into the endoplasmic reticulum (ER) for loading on to class I MHC molecules. In the absence of peptide loading, newly formed heterodimeric class I MHC molecules are unstable, that leads to their dissociation and subsequent sequestration of class I alpha chains in the endoplasmic reticulum (ER), resulting ultimately in a reduction in class I MHC molecules expressed on the cell surface. Hence, the removal of ICP47 should be advantageous for HSV-1-based vectors constructed to deliver immune stimulatory activities.
To verify that the transgene-interrupted ICP47 gene of HX86 lacked the ability to produce the activities associated with wild-type ICP47, Gombos cells were infected with HX86 or the ICP47-containing control vector THZ.
) and class I MHC expression was measured by flow cytometry. HX86-infected cells exhibited class I surface expression equal to or higher than uninfected control cells (Figure 8a and c) . In contrast, Gombos cells infected with THZ.3 showed less surface expression, the anticipated effect of ICP47 expression from this virus (Figure 8a and b) . These observations confirmed that HX86 does not interfere with the appearance of MHC class I antigens on the cell surface.
Discussion
The need for multigene vectors will likely increase as observations using related individual genes for gene therapy applications accumulate. It is already apparent that intervention at multiple stages in complex disease processes may be more effective using multiple genes whose products ameliorate different aspects of the associated pathology. Examples include control of cancer growth and spread, management of inflammatory processes and enhancement of tissue growth and repair. This study describes the development of replication-defective HSV-1 gene vectors in which the mutant vector background allows for simultaneous, high-level expression of selected sets of multiple transgenes. The defective mutant vector was deleted for 11.6 kb of viral sequences eliminating nine viral functions, including four of five IE gene products. Deletion of the IE genes substantially reduced vector cytotoxicity and limited viral gene expression to the remaining IE gene ICP0 and the IE/E gene ICP6 (U L 39) encoding the large subunit of the viral ribonucleotide reductase. The vector was engineered to express simultaneously as many as five transgenes inserted into separate viral loci, resulting in the addition of 12.0 kb of new sequence, thereby restoring the viral genome to near wild-type length. The transgenes were selected as a model set of gene functions based on their individual reported roles in either the activation of cytotoxic anticancer drugs or the induction of antitumor immunity, which suggested that they could potentially behave in a synergistic fashion in cancer gene therapy applications. The transgenes were each transcribed from functionally independent HSV or HCMV IE promoters chosen for their ability to be activated upon viral genome entry into the nucleus in the absence of de novo viral protein synthesis. HX86Z and HX86G are our most advanced HSV vectors, to date, in terms of their ability to simultaneously express multiple transgenes and demonstrate the potential for using HSV-1 vectors for the expression of highly complex sets of functional gene products.
The construction of multigene vectors is a complex and potentially daunting task and thus procedures must be developed to streamline the process. To meet this challenge, we developed procedures by which vectors can be engineered using flexible components that can be both manipulated individually and recombined to create new sets of transgene combinations. We achieved this by exploiting a previously described method to delete viral gene functions by reporter gene insertion (lacZ) which permits efficient subsequent exchange with any transgene. We have shown here that this method is also effective for the sequential introduction of multiple transgenes. 38 We found that it was convenient to construct two independent vector subsets, one with transgenes introduced into the left-hand portion of an ICP4/ICP27-defective genome containing a lacZ gene at the ICP22 locus (eg HGZ.25, Figure 1a ) and the other with transgenes inserted in the right-hand portion of an ICP4-defective genome (eg 7H10, Figure 1a ). On coinfection, these mutants efficiently recombined to produce single vectors containing both the left-hand and right-hand transgenes.
Figure 8 FACS analysis for class I MHC surface expression on infected and uninfected Gombos cells. 2 × 10 5 Gombos cells were mock-infected (a), or infected with THZ.3 (b) or HX86 (c) at an MOI of 5, then plated. At 24 h PI, the cells were washed, trypsinized and stained for class I MHC surface expression using specific FITC-conjugated antibodies. Samples were analyzed by FACS and the results are displayed as relative fluorescence.
These vectors could be readily identified on the basis of their blue-plaque phenotypes and their patterns of infection on cell lines that complemented the IE genes ICP4, ICP27 or both ICP4 and ICP27. The recombinants of interest were double mutants and would grow only on double-complementing 7B cells. 24 Together, these procedures provided a highly flexible technology for vector construction, representing a substantial improvement over previous technologies that require considerable effort to construct even a single transgene-containing vector. We established that the lacZ insertion/substitution method could be used with vectors already carrying multiple transgenes (eg the derivation of HX86Z from HX86) and that the set of transgenes in a multigene vector could be altered by exchanging an existing transgene for a new transgene (eg the derivation of HX86G from HX86Z).
An important consideration in the design of multigene vectors is the mutant vector background and its effect on transgene expression. It was essential to select a vector background that does not immediately destroy the cell, thereby rapidly curtailing transgene product formation. Recent studies have shown that simultaneous deletion of multiple HSV-1 IE genes can reduce virus toxicity for tissue culture cells. For example, a mutant deleted for ICP4, ICP22 and ICP27 was found to be less toxic to Vero cells in culture than mutants deleted for single IE genes. 24, 25, 27 This multiple IE gene deletion mutant was shown to express ICP0 over a longer time period which was associated with arrest of DNA synthesis and cell division. 27 Although ICP0 may have some cytotoxic properties, the presence of ICP0 may be important to achieve high-level short-term transgene expression. For example, a mutant deleted for ICP0, ICP4 and ICP27 that contained a lacZ reporter gene under control of the ICP0 promoter was reported to express ␤-galactosidase only at low levels despite the fact that this mutant was considerably less cytotoxic than a mutant deleted for ICP4, ICP22 and ICP27. 26 Thus, although it is likely that deletion of all of the IE genes will create a suitable vector background for applications that require transduction without interference with cell metabolism, it remains to be determined whether such vectors will adequately support transgene expression, a problem that has previously been encountered with highly defective adenovirus vectors. [45] [46] [47] The results in this paper validate our choice of the ICP4/22/27 deletion mutant background for multigene vector construction. First, the HX86 vector containing four different transgene expression cassettes with three different promoters at four different loci was found to express all four transgenes simultaneously for up to 7 days with maximum expression occurring at 2-3 days PI. Second, the cytotoxicity of our mutant vectors with multiple IE gene deletions for the human melanoma cell line Gombos (as well as four other independent human lines (Krisky and Glorioso, unpublished) was substantially less than that of a single IE gene deletion mutant. Infection of Gombos cells with single IE gene ICP4
− mutants caused rapid killing with few viable cells remaining by 3 days PI, whereas the triple IE mutant HX86 did not result in rapid cell death, with approximately 50% of cells remaining viable for at least 4 days. Third, the enhanced cell viability observed following infection with the triple IE gene deletion mutant was accompanied by a dramatic increase in the expression of individual transgenes. Expression was improved both in terms of peak levels and duration compared with isogenic expression cassettes carried by mutants deleted for ICP4 alone. It should be noted that the observed increases in expression were greater than what could be ascribed to cell survival alone. This could be due to sustained expression of ICP0, the promiscuous activator of transcription, 15, 16 which occurs in the absence of the other IE gene products. 26 Other considerations in the design of multigene vectors concern the choice of transgene promoters and whether the number of transgene cassettes or the locus of transgene insertion affects the level of expression of individual transgenes. Wild-type HSV contains six genes, two of which are diploid, that are transactivated immediately on infection by the tegument protein VP16 in collaboration with cellular transcription factors. 5, [48] [49] [50] The products of several of these IE genes (eg ICP4 and ICP22) regulate the level of expression of other IE genes and also influence transcription of cellular genes. [6] [7] [8] 10 This suggests that any number of transgenes introduced into HSV under control of IE gene promoters could be expressed provided that either ICP0 or a functionally similar transactivator is available. In the present study, we found that the tk, lacZ, hGM-CSF and hIFN␥ genes were all expressed at high levels using HSV IE promoters. Moreover, the IE promoter from another herpesvirus, HCMV, was effective for transient transgene expression. We also determined that expression of one gene, hGM-CSF, from the multiply deleted mutant vector background was comparable among viruses containing three, four or five transgenes, indicating that the insertion of additional expression cassettes did not substantially reduce the level of expression of an individual gene. However, we did observe a small (two-fold) decrease with the five-transgene vector which can be ascribed to reduced transduction efficiency. Thus, the fifth transgene was inserted into the gC locus encoding the principal envelope glycoprotein used for recognition of heparan sulfate-containing cell surface proteoglycans, the first contact receptors for HSV-1. [40] [41] [42] We and others have observed that the ratio of infectious particles to total particles is reduced when gC is absent from the virus envelope. 41, 51, 52 These results illustrated, therefore, that the locus of transgene insertion is an important consideration not only because it can affect virus production, but also because it can diminish the efficiency of transgene delivery.
There are numerous other sites for gene insertion into HSV-1 which do not require the deletion of essential viral functions and do not strictly require viral gene complementation. As already noted for the gC locus, however, the removal of nonessential genes is not without consequence since many contribute to efficient viral growth even in cell culture and their deletion can lower vector titers or vector infectivity. Some nonessential functions are likely to require complementation when large numbers of these genes are eliminated from the viral genome. To reduce production problems related to inefficient vector growth, we have inserted transgene cassettes into viral loci whose functional loss does not lead to a substantial reduction in available virus titers (unpublished work). This included loci whose products contribute to viral DNA synthesis in nondividing cells, such as the thymidine kinase and ribonucleotide reductase genes, as well as a number of the nonessential glycoprotein genes. For example, we have simultaneously removed all the nonessential U S genes, including four glycoprotein genes, without substantially compromising virus growth 53 (Laquerre and Glorioso, unpublished) . The virus host shut-off function encoded by U L 41 has also proved to be a convenient site for transgene insertion since removal of this function has little effect on virus growth. The U L 41 gene encodes a structural protein of the virus tegument that destabilizes both viral and cellular mRNA, 32-34 and we have found that its removal can improve transgene expression in some cell types (Krisky and Glorioso, unpublished observation). Finally, the latency locus is not required for transgene expression, providing another site for transgene insertion, and the latency-specific promoter appears promising for expression of transgenes in the nervous system. [54] [55] [56] [57] Taking advantage of all available sites, it should be possible to construct vectors having as much as 50 kb of foreign DNA, but such highly defective mutants have not yet been constructed.
The experiments in this study describe the development of a vector background that should be useful for transient high-level expression of multiple transgenes. The combination of transgenes can be readily modified to produce vectors with different sets of transgenes tailored to meet the demands of specific applications. The vector background used in our work combines the features of cell growth arrest and reduced cytotoxicity, making it attractive for certain applications. For example, it may prove advantageous to infect tumor cells in vivo with vectors that both arrest tumor growth and secrete immunomodulatory cytokines that enhance the recruitment of tumoricidal inflammatory cells and responder T cells capable of developing tumor-specific immunity. Our multigene vectors provide the tools to express simultaneously multiple foreign gene products, selected for their potential to act synergistically towards a desired biological effect. To demonstrate the utility of these multigene vectors in combination gene therapy, experiments in tumor models are now underway to evaluate the efficacy of the multi-transgene antitumor vectors described here in comparison with vectors expressing the same transgenes individually.
Materials and methods
Transgene plasmid constructs Plasmids used for the insertion of HCMV IEp-PacI lacZ construct into the ICP22 (pB5) and ICP47 (pZ1) loci have been described elsewhere. 38 Plasmid p6B7.1 used for the insertion of HCMV:IEp-hB7.1 into the ICP22 locus was created by replacing the lacZ-SV40pA cassette of pB5 with the coding sequence from hB7.1 as a ClaI-XbaI fragment. Plasmid pL1 was used for recombination of a HCMV:IEp human interleukin 2 (hIL-2) expression construct into the ICP47 locus. Plasmid pL1 was produced by inserting a fragment containing the HCMV:IEp hIL-2 construct from pC12.4 into pKO6, a plasmid carrying a BglII-EcoRI ICP47 boundary fragment with an NcoIApaL1 internal deletion of the ICP47 structural gene. The hIL-2 expression cassette consisted of the following tandem segments: HCMV:IEp, rabbit ␤-globin intron, hIL-2 (PstI-StuI), rabbit ␤-globin 3Ј untranslated region (UTR), and SV40 early polyadenylation (pA) signal. pIL-2 was constructed by insertion of hIL-2 (PstI-StuI) from ATCC 39673 pTCGF-11 (Genetics Institute, Cambridge, MA, USA) into PstI-EcoRV-digested pSP72 (Promega, Madi-son, WI, USA). The hIL-2 sequence was then removed from pIL-2 PstI-BglII and cloned into pUC19 (New England Biolabs, Beverly, MA, USA) in which the unique HincII site was changed to a BglII site resulting in plasmid pI. pLU was created by insertion of a BglII-BamHI fragment containing the rabbit ␤-globin 3Ј UTR fused to an SV40 pA (pRSV-␤-globin; ATCC 37200) into the BamHI site of pI. The human HCMV:IEp was cloned into pBSSK II (Stratagene, La Jolla, CA, USA) as a SalI-ClaI fragment from pRC2 (pRC-CMV (Invitrogen, Carlsbad, CA, USA) with a unique HindIII site changed to a ClaI site) resulting in the production of pHSC. The hIL-2 -␤-globin 3Ј UTR -SV40 pA was cloned into pHSC as a PstI-BamHI fragment in order to produce pC1. After destruction of the PstI site of pC1, the rabbit ␤-globin intron was cloned into pC1 as a HindIII-EcoRI fragment to produce pC12.4. In order to remove the IL-2 construct for insertion into pKO6, the SalI site of pC12.4 was changed to a PstI site then removed as a PstI-NotI fragment and cloned into pKO6 creating pL1. The plasmid construct used for deletion of a SmaI fragment of U L 41 which contains an ICP0 IEp PacI lacZ expression construct has been described previously (p41ICP0LacZ). 38 This plasmid was used for creation of an ICP0-hGM-CSF expression construct with U L 41 flanking regions for recombination. The hGM-CSF coding sequence was cloned into p41ICP0LacZ as an EcoRI-XbaI fragment which was produced by EcoRI-XbaI digestion of the product from PCR amplification of hGM-CSF from pcDhGM/Eo-CSF (ATCC 57594) with the following primers: 5Ј GGA ATT CCA GGA TGT GGC TGC AGA GC 3Ј and 5Ј GCT CTA GAG CGA CCA TCC TGA GTT TCT AGC T 3Ј to produce p410G.1.
Cells and recombinant viruses
Human melanoma cells (Gombos) were kindly provided by J Kirkwood, University of Pittsburgh. All viral constructs were generated by viral cross or marker transfer through the use of standard methods or the recently described PacI method. 38 These modifications were carried out in 7B cells, a previously described Vero cell line capable of providing the essential ICP4 and ICP27 IE gene products in trans. 24 All marker transfer recombinations were carried out using standard calcium phosphate transfection of 5 g viral DNA and 1 g linear recombination plasmid containing the transgene cassette. Viral crosses were performed by coinfection of 7B cells at a MOI of 5 of each virus followed by harvest at 18 h PI. All resultant viral mutants were purified by three rounds of limiting dilution and verified by Southern blot analysis of the vector DNA. Viral stocks were prepared and titrated using 7B cells as described previously. 24 The U L 41 − KOS vector was graciously provided by GS Read.
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Virus particle to infectious virus ratios Crude viral suspensions were pelleted, fixed in 2.5% glutaraldehyde in phosphate-buffered saline, post-fixed with 1% osmium tetroxide, dehydrated and embedded in Epon. Utrathin, 60 nm sections, were cut using a Reichert Ultracut E ultramicrotome, mounted on grids, and double-stained with 2% uranyl acetate (7 min) and 1% lead citrate (3 min). Observation was with a JEOL 1210 electron microscope. Random fields were photographed at 10 000× and enlarged to 25 000. Viral particles were counted, by an experienced microscopist on each of five fields for each sample and the mean found. As the starting volume of viral suspension and the volume of each image field is known this number was extrapolated back to total viral particles per volume of suspension and compared with infectious virus using standard plaque assay on complementing cells.
Transgene expression assays
In order to assess transgene expression, cells were infected with virus in solution at the MOI indicated for 1 h at 37°C with agitation and then plated. For measurement of cytokine expression, media were removed at 24 h intervals and frozen at −80°C until assayed for transgene product. hGM-CSF and hIL-2 levels were quantified by ELISA (hGM-CSF ELISA; Endogen, Cambridge, MA, USA; hIL-2 ELISA; Genzyme, Cambridge, MA, USA). hB7.1 expression was measured by FACS analysis at 24 h PI using anti-hB7.1 (BB-1/B7-1 monoclonal, Becton Dickonson, San Jose, CA, USA) and FITC-conjugated anti-mouse IgG antibodies. Class I MHC levels were measured by FACS analysis using monoclonal anti-human HLA class I antigen -FITC-conjugated antibody (Sigma Immunochemicals, St Louis, MO, USA). ␤-Galactosidase expression was measured by ONPG assay while the quantity of ␤-gal protein per sample was determined by BCA protein assay (Pierce, Rockford, IL, USA). HSVtk activity was assessed indirectly by GCV-induced cell death. Cells were infected with virus in solution at the indicated MOI for 1 h at 37°C with agitation, then plated. GCV was added to selected cultures at 10 mg/ml medium. At 24 h intervals, cultures were washed with PBS, trypsinized, and the number of remaining viable cells determined using trypan blue staining to exclude dead cells. HSVtk production was also determined by Western blot analysis. After infection, proteins were separated on 12% SDS-PAGE gels and transferred to nitrocellulose by electroblotting. Polyclonal anti-HSVtk antibodies (gift of WC Sumners, Yale University) were used at 1:500 dilution. Anti-mouse alkaline phosphatase conjugated secondary antibody (Sigma) was used at 1:5000 dilution and proteins were visualized using nitro blue tetrazolium chloride (NBT) (Sigma) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma).
